Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Zscaler Inc (ZS) Price & Performance

Merck & Co., Inc.Trade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Zscaler Inc — how do they compare? Merck & Co., Inc. trades at $148.18 (market cap $366.28B), while Zscaler Inc trades at $166.12 (market cap $26.41B). The key difference: Merck & Co., Inc. is far larger — about 13.9× Zscaler Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.

MRKZS
Market Cap
$366.28B$26.41B
Sector
HealthTechnology
52-Week High
$156.43$336.27
52-Week Low
$77.60$118.05
Enterprise Value
$413.04B$24.79B
Dividend Yield
2.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.

The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.

Zscaler Inc

Zscaler (ZS) trades at $161.94, down 4.63% amid bearish technical signals despite strong quarterly earnings beats. The stock shows improving fundamentals with revenue growing from $1.1B in 2022 to $2.67B in 2025, though net margins remain negative. Recent news highlights Zscaler's AI security innovations and conference presentations, while analyst consensus remains strongly bullish with a $204.88 price target representing 26% upside potential.

Zscaler presents a compelling growth story with accelerating revenue and strong enterprise adoption, though profitability challenges and elevated valuation metrics warrant caution. The stock's current weakness near support levels offers potential entry points for investors bullish on cybersecurity demand, particularly given Zscaler's leadership in zero-trust security and AI-driven threat protection capabilities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS